Technology and Procedures – Genomic Testing Cooperative

Genomic Testing Cooperative (GTC) to Share 12 Ground-breaking Abstracts at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando

December 2, 2025

Lake Forest, CA — December 2, 2025 — Genomic Testing Cooperative (GTC), a leading provider of integrated DNA and RNA next-generation sequencing (NGS) solutions for hematologic tumors and liquid biopsy applications, today announced that its work and data will be presented in 12 abstracts at the ASH 2025 Annual Meeting

Myelodysplastic Syndrome (MDS)

June 26, 2019

MDS is defined as ineffective hematopoiesis characterized by adequate or increased hematologic elements in bone marrow with peripheral cytopenia. Therefore, the presence of cytopenia in one or more hematologic lines is necessary for the diagnosis of MDS. However, numerous reactive conditions other than MDS can cause cytopenia and these conditions

The FDA has Approved Drugs for FGFR Abnormalities

May 27, 2019

The FDA has approved Balversa (erdafitinib) as a treatment for adult patients with locally advanced or metastatic bladder cancer that have FGFR3 or FGFR2 abnormalities and that has progressed during or following prior platinum-containing chemotherapy. Urothelial tumors have been reported to show abnormalities in FGFR3 (22%), FGFR1 (8%), and FGFR2

GTC Presents at the 2019 ASCO Annual Meeting

May 22, 2019

Genomic Testing Cooperative (GTC) and Collaborators to Present data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019 ASCO Annual Meeting Irvine, California – May 22, 2019 – Genomic Testing Cooperative, LCA. today announced that data using its unique DNA and RNA profiling will

Study shows that RNA Plus DNA profiling significantly enhanced Drug Matching

May 16, 2019

Recent study published in Nature Medicine (Rodon et al, Nature Medicine volume 25, pages 751–758, 2019) showed that molecular profiling using both DNA and RNA significantly enhanced therapy recommendation and patient outcome. A third of the studied patients got drug therapy recommendation when both RNA and DNA testing was performed.

Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers | ASH ANNUAL MEETING ABSTRACT

November 29, 2018

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations. Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib Program: Oral and Poster Abstracts | Monday, December 3, 2018: 11:45 AMType: OralSession: 642. CLL: Therapy,

Venetoclax in Combination with FLAG-IDA Chemotherapy (FLAG-V-I) for Fit | ASH ANNUAL MEETING ABSTRACT

November 28, 2018

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Program: Oral and Poster Abstracts | Monday, December 3, 2018, 6:00 PM-8:00 PMSession: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Background: Venetoclax (VEN) is a potent and selective small molecule BCL2 inhibitor,

Acute Myeloid Leukemia | ASH Annual Meeting Abstract

November 26, 2018

Session: 613. Acute Myeloid Leukemia: Clinical Studies: Poster I Molecular Epidemiologic Associations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) within the United States Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Saturday, December 1, 2018, 6:15 PM-8:15 PM | Hall GH (San

Tag: Technology and Procedures